Vote Scores

Home / Companies / TAKEDA PHARMACEUTICAL CO LTD / 26 Jun 2024

Meeting · year to 30 June 202431 filers reporting

TAKEDA PHARMACEUTICAL CO LTD: meeting of 26 Jun 2024

Votes reported on Form N-PX, item by item

31 Form N-PX filers reported votes at the TAKEDA PHARMACEUTICAL CO LTD meeting of 26 Jun 2024. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

14 nominees; 91.6% of reported votes for; 9 filers withheld from or voted against at least one nominee.

323 vote records from 19 filers. 1 of the 19 filers that marked the item either way voted against management.

94.7% for5.3% against5.3% against management19 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

7 vote records from 7 filers. 0 of the 7 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management7 filers100.0% for0.0% against0.0% against management3,083 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

7 vote records from 6 filers. 0 of the 6 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management6 filers92.7% for7.3% against7.3% against management385,994 reported shares
4

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

21 vote records from 17 filers. 0 of the 17 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management17 filers100.0% for0.0% against0.0% against management1,220,947 reported shares, counted once per item in this group
5

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

19 vote records from 16 filers. 9 of the 16 filers that marked the item either way voted against management.

43.8% for56.3% against56.3% against management16 filers39.4% for60.6% against60.6% against management1,020,742 reported shares, counted once per item in this group
6

Several categoriesSecurity holder

Shareholder proposals (not separable from the filings)

Filers described these proposals in wordings that could not be matched to one another, so they are shown together.

2 vote records from 1 filers. 0 of the 1 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management1 filers100.0% for0.0% against0.0% against management1,036 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors
VanguardFor
DimensionalFor
American CenturyFor
Capital Group and American FundsFor
AllianceBernsteinFor
VirtusFor
VanEckFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the TAKEDA PHARMACEUTICAL CO LTD meeting?

31 Form N-PX filers reported votes at the meeting of 26 Jun 2024. On say-on-pay, 0 of 7 voted against management (0.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by TAKEDA PHARMACEUTICAL CO LTD on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for TAKEDA PHARMACEUTICAL CO LTD

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing TAKEDA PHARMACEUTICAL CO LTD with a meeting date within three days of 26 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.